Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. reported results from its 2026 annual stockholder meeting. Stockholders approved the Fulgent Genetics, Inc. 2026 Equity Incentive Plan, which authorizes issuance of 2,000,000 new shares of common stock, plus up to 1,500,000 additional shares if awards under the prior plan are forfeited or cancelled on or after the effective date.
The 2026 Plan replaces the Amended and Restated 2016 Omnibus Incentive Plan, although existing awards under the prior plan remain in effect under their current terms. Stockholders also elected four directors to serve until the 2027 annual meeting, ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
At the meeting, a quorum of 24,578,996 shares, or approximately 83% of the 29,747,420 shares outstanding and eligible to vote as of March 20, 2026, was present in person or by proxy, indicating strong stockholder participation.
Fulgent Genetics reported first quarter 2026 revenue of $71.1 million, down modestly from $73.5 million a year earlier, with a GAAP net loss of $24.8 million, or $(0.80) per share. Non-GAAP net loss was $11.0 million, or $(0.36) per share, and adjusted EBITDA loss was $15.2 million.
The company ended the quarter with $604.7 million in cash, cash equivalents, restricted cash and marketable securities and used $40.1 million to repurchase about 2.6 million shares. For full-year 2026, Fulgent expects revenue of roughly $350 million, a non-GAAP loss of about $46 million (≈$(1.59) per share), and year-end cash and investments of about $636 million, assuming receipt of approximately $106 million in tax refunds.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported a routine tax-related share disposition. On the vesting of restricted stock units assumed in a prior merger, 1,645 shares of common stock were withheld to cover tax withholding obligations at $16.31 per share.
Following this tax-withholding event, Gao directly holds 993,007 shares of Fulgent Genetics common stock. This withholding is an administrative mechanism tied to equity compensation and does not represent an open-market purchase or sale.
Fulgent Genetics, Inc. President and COO Jian Xie reported routine tax-related share withholding tied to equity compensation. On this Form 4, 4,361 shares of common stock were withheld at $16.31 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a prior merger.
After this tax-withholding disposition, Xie holds 370,952 common shares directly. In addition, a trust associated with him, The Hsieh Family Dynasty Trust, holds 220,816 shares indirectly; Xie serves on the trust’s investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On April 26, 2026, 2,747 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously assumed restricted stock units under a prior merger agreement. Following this withholding, Kim directly holds 365,800 shares of Fulgent common stock, indicating he retained a substantial equity position and did not report an open-market sale in this filing.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, through The Ming Hsieh Trust, unwound a prepaid variable forward arrangement involving 750,000 shares of common stock. The trust had previously entered this forward contract with an unaffiliated bank in August 2023.
On March 9, 2026, the Hsieh Trust elected to cancel the agreement for all 750,000 shares and paid an aggregate of $10,708,875 to the bank. After this payment and cancellation, those 750,000 shares held by the trust are no longer pledged to the bank.
Following the reported positions, Ming Hsieh holds 900,634 shares directly and has additional indirect holdings, including 7,895,115 and 220,816 shares held by trusts, plus smaller positions of 1,000 shares each in a minor’s account and by an immediate family member.
Ming Hsieh, Chief Executive Officer and Chair of Fulgent Genetics, Inc., reports beneficial ownership of 8,867,303 shares of common stock, representing 30.74% of the 28,844,618 shares outstanding as of March 27, 2026. This includes 7,895,115 shares held by The Ming Hsieh Trust, which alone represents 27.37% of the company’s common stock.
Since the prior amendment, Hsieh’s position changed mainly through the vesting of multiple restricted stock unit awards and performance-based RSUs, with a portion of shares sold or withheld to cover tax obligations. The Trust also terminated two pre-paid forward arrangements covering a total of 1,550,000 shares. A large block of Trust shares remains pledged as security under a pre-paid forward arrangement and as collateral for a credit facility, and Hsieh shares voting and dispositive power over additional shares held by a Dynasty Trust and an immediate family member.
Fulgent Genetics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 14, 2026 at 9:00 a.m. Pacific Time in El Monte, California. Investors will elect four directors for one-year terms, ratify Deloitte & Touche LLP as auditor for 2026, cast an advisory vote on named executive officer pay, and vote on the new 2026 Equity Incentive Plan. The proxy details ownership levels, with directors and executive officers as a group holding a significant stake, outlines board committee structure and independence, and explains the company’s pay-for-performance philosophy, risk controls, and cybersecurity and sustainability oversight.